CYP2E1
氯唑沙宗
化学
药理学
体内
生物信息学
生物化学
体外
微粒体
生物
生物技术
基因
作者
Shipra Bhatt,Vinay Kumar,Ashish Dogra,Probir Kumar Ojha,Priya Wazir,Payare L. Sangwan,Gurdarshan Singh,Utpal Nandi
出处
期刊:Xenobiotica
[Taylor & Francis]
日期:2021-02-15
卷期号:51 (6): 625-635
被引量:19
标识
DOI:10.1080/00498254.2021.1883769
摘要
CYP2E1 is directly or indirectly involved in the metabolism of ethanol and endogenous fatty acids but it plays a major role in the bio-activation of toxic substances that produce reactive metabolites leading to hepatotoxicity. Therefore, identification of CYP2E1 inhibitor from bioflavonoids class having useful pharmacological properties has dual benefit regarding avoidance of severe food-drug/nutraceutical-drug interaction and scope to develop a phytotherapeutics through an intended pharmacokinetic interaction.In the present study, we aimed to identify CYP2E1 inhibitor from experimental bioflavonoids which are unexplored for CYP2E1 inhibition till date using in-silico, in-vitro and in-vivo approaches.Results of in-vitro CYP2E1 inhibitory studies using CYP2E1-mediated chlorzoxazone 6-hydroxylation in human liver microsomes showed that glabridin have the highest potential than fisetin, epicatechin, nobiletin, and chrysin to inhibit CYP2E1 enzyme. Mechanistic investigations indicate that glabridin is a competitive CYP2E1 inhibitor. Molecular docking study results demonstrate that glabridin strongly interacted with the active site of human CYP2E1 enzyme. Pharmacokinetics of a CYP2E1 substrate in mice model indicates a significant alteration of chlorzoxazone and 6-hydroxychlorzoxazone plasma levels in the presence of glabridin. Further studies are needed to confirm the results at clinical level.Overall, glabridin is found to be a potential CYP2E1 inhibitor.
科研通智能强力驱动
Strongly Powered by AbleSci AI